Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
NCT07151937Phase 2Recruiting
- Sponsor
- Almirall
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ALM27134 in hidradenitis suppurativa (HS), sponsored by Almirall. Started Nov 2025; status: recruiting.
02
Drugs
ALM27134
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07151937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07151937.